- WuXi Biologics and Sinorda Biomedicine have entered a strategic collaboration to develop and manufacture SND006, a bispecific antibody for inflammatory bowel disease and other autoimmune conditions.
- The partnership will support preclinical development, clinical supply, and IND filings in China and the United States, with plans to expand collaboration across Sinorda’s pipeline.
WuXi Biologics has entered into a strategic collaboration with Sinorda Biomedicine to support the development and manufacturing of SND006, a novel bispecific antibody being developed for the treatment of inflammatory bowel disease and other autoimmune diseases.
Under the agreement, Sinorda Biomedicine will use WuXi Biologics’ biologics development and manufacturing capabilities to advance preclinical pharmacology studies and produce clinical supply for SND006. The collaboration is intended to accelerate preparation of Investigational New Drug applications.
SND006 is an independently developed bispecific antibody for which Sinorda Biomedicine holds worldwide rights. The company has completed in vitro functional validation studies and plans to submit IND applications to China’s National Medical Products Administration and the US Food and Drug Administration in 2026.
The collaboration also establishes a framework for future joint projects across Sinorda Biomedicine’s pipeline, spanning activities from molecule discovery through to clinical manufacturing using WuXi Biologics’ integrated CRDMO platform.
“We are pleased to accelerate the development and manufacturing of Sinorda Biomedicine’s innovative bispecific antibody SND006 through our integrated technology platforms and comprehensive capabilities.”
Dr. Chris Chen, CEO of WuXi Biologics
